Previous close | 122.70 |
Open | N/A |
Bid | 137.90 |
Ask | 146.90 |
Strike | 300.00 |
Expiry date | 2024-07-19 |
Day's range | 122.70 - 122.70 |
Contract range | N/A |
Volume | |
Open interest | 1 |
Vertex Pharmaceuticals beat Wall Street estimates for first-quarter profit on Monday, driven by robust uptake for its blockbuster cystic fibrosis treatments. Cystic fibrosis (CF) - an inherited disorder that causes severe damage to the lungs, digestive system and other organs - affects an estimated 105,000 people across 94 countries, according to data from U.S.-based CF Foundation. Vertex reported adjusted earnings per share of $4.76 on revenue of $2.69 billion, topping market estimates $4.06 on revenue of $2.58 billion, according to LSEG data, for the quarter ended March 31.
Comprehensive Analysis of Vertex Pharmaceuticals' Financial Performance and Strategic Initiatives
Vertex (VRTX) delivered earnings and revenue surprises of 16.10% and 5.15%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?